PNI is a global leader in ushering in the next wave of genetic medicines in infectious diseases, cancer, and rare diseases. We work with the world’s leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.
Gene-modified cell therapy has historically been achieved using viral vectors for ex vivo gene delivery, with approved drugs such as Kymriah® or Yescarta® demonstrating the success of autologous cell therapies. However, both safety concerns and ... Continued